ClinicalTrials.gg
CompletedNCT01023841Updated Apr 17, 2019Results posted

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

A Phase 4 interventional study of bimatoprost ophthalmic solution 0.03% and Vehicle Sterile Solution in Eyelash Hypotrichosis and Alopecia Areata, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
30th of 84
71 · median 46
Started
2010
the only one that year
Phase 4
8 of 98
none open now
Registered
10th of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 30th largest by enrollment of the 84 interventional ones that give a count, is the only one that started in 2010, is one of 8 in phase 4, and was the 10th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough eyelashes) in children.

03

Conditions studied

  • Eyelash Hypotrichosis
  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children who have inadequate eyelashes or have lost their eyelashes as a result of chemotherapy treatment, who completed their chemotherapy (intensive treatment) at least 4 weeks before starting the study, are considered to be at low risk for relapse of their cancer, and are well enough to complete the study
  • Children who have minimal to moderate inadequate eyelashes due to alopecia areata
  • Adolescents between the ages of 15-17 years who have minimal to marked inadequate eyelashes

Exclusion criteria

Exclusion Criteria:

  • Any eye disease or abnormality, eye surgery, permanent eyeliner, eyelash implants.
  • Semi-permanent eyelash tint, dye or eyelash extension application within 3 months
  • Use of over the counter eyelash growth products within 6 months.
  • Use of prescription eyelash growth products (eg, Latisse®)
  • Any eye condition that would prevent required ophthalmology exams
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
71 participants (actual)

Study arms

  • Active comparator
    bimatoprost ophthalmic solution 0.03%

    One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.

    Drug: bimatoprost ophthalmic solution 0.03%

  • Placebo comparator
    Vehicle Sterile Solution

    One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.

    Drug: Vehicle Sterile Solution

Interventions

  • One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.

    Also known as: LATISSE®

  • DrugVehicle Sterile Solution

    One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events

    An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.

    Time frame: 5 Months

  2. Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score

    The physician evaluated the overall eyelash prominence in both eyes using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked. A 1-grade improvement in the GEA score from Baseline indicated improvement.

    Time frame: Baseline, Month 4

Secondary outcomes

  1. Change From Baseline Upper Eyelash Length as Measured by Digital Image Analysis (DIA)

    Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement).

    Time frame: Baseline, Month 4

  2. Change From Baseline in Upper Eyelash Thickness as Measured by DIA

    Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was assessed across both eyes as an average and is measured in millimeters squared (mm\^2). A positive change from Baseline indicated fuller eyelashes (improvement).

    Time frame: Baseline, Month 4

  3. Change From Baseline in Upper Eyelash Darkness as Measured by DIA

    Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness (intensity) was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).

    Time frame: Baseline, Month 4

07

Results

Posted Sep 13, 2013

Participant flow

Participant flow — Overall Study
MilestoneBimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Started4823
Completed4723
Not completed10

Outcome measures

PrimaryPercentage of Participants With Adverse Events

An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.

Time frame:
5 Months
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events
Percentage of participantsBimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Percentage of Participants With Adverse Events35.443.5
SecondaryChange From Baseline Upper Eyelash Length as Measured by Digital Image Analysis (DIA)

Photographs were taken of the eyelashes and assessed using DIA. Length was measured in millimeters (mm). Data from both eyes were averaged for each participant for analysis. A positive change from Baseline indicated longer length (improvement).

Time frame:
Baseline, Month 4
Reported as:
Mean · mm
Change From Baseline Upper Eyelash Length as Measured by Digital Image Analysis (DIA)
mmBimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Baseline6.83 ± 2.5686.04 ± 2.915
Change from Baseline at Month 41.12 ± 1.6260.67 ± 1.846
SecondaryChange From Baseline in Upper Eyelash Thickness as Measured by DIA

Photographs were taken of the eyelashes and assessed using DIA. Eyelash thickness (fullness) was assessed across both eyes as an average and is measured in millimeters squared (mm\^2). A positive change from Baseline indicated fuller eyelashes (improvement).

Time frame:
Baseline, Month 4
Reported as:
Mean · mm^2
Change From Baseline in Upper Eyelash Thickness as Measured by DIA
mm^2Bimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Baseline1.20 ± 0.7381.18 ± 0.862
Change from Baseline at Month 40.41 ± 0.5350.05 ± 0.449
SecondaryChange From Baseline in Upper Eyelash Darkness as Measured by DIA

Photographs were taken of the eyelashes and assessed using DIA. Eyelash darkness (intensity) was measured in both eyes and averaged for analysis using a scale where 0=black and 255=white. A negative change from Baseline indicated darker eyelashes (improvement).

Time frame:
Baseline, Month 4
Reported as:
Mean · Intensity units
Change From Baseline in Upper Eyelash Darkness as Measured by DIA
Intensity unitsBimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Baseline143.78 ± 20.446143.44 ± 25.844
Change from Baseline at Month 4-15.34 ± 15.724-5.47 ± 12.289
PrimaryPercentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score

The physician evaluated the overall eyelash prominence in both eyes using the GEA 4-point scale: 1= minimal, 2= moderate, 3= marked and 4= very marked. A 1-grade improvement in the GEA score from Baseline indicated improvement.

Time frame:
Baseline, Month 4
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score
Percentage of participantsBimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Percentage of Participants With at Least a 1-Grade Improvement From Baseline in the Global Eyebrow Assessment (GEA) Score70.826.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimatoprost Ophthalmic Solution 0.03%—0/48 (0%)0/48 (0%)
Vehicle Sterile Solution—0/23 (0%)1/23 (4.3%)
Most frequent other events
Most frequent other events
EventBimatoprost Ophthalmic Solution 0.03%Vehicle Sterile Solution
Ovarian cyst rupturedReproductive system and breast disorders0/371/16

Baseline characteristics

Age, Customized
Age, Customized(participants)Bimatoprost Ophthalmic Solution 0.03%Vehicle Sterile SolutionTotal
5-11 years639
12-17 years422062
Sex: Female, Male
Sex: Female, Male(Participants)Bimatoprost Ophthalmic Solution 0.03%Vehicle Sterile SolutionTotal
Female371653
Male11718
08

Study locations

2 sites
  • Newport Beach, California, United States
  • São Paulo, Brazil
09

References and documents

Publications

  • Borchert M, Bruce S, Wirta D, Yoelin SG, Lee S, Mao C, VanDenburgh A. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects. Clin Ophthalmol. 2016 Mar 10;10:419-29. doi: 10.2147/OPTH.S89561. eCollection 2016. PubMed 27022239 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2010 to primary completion in Nov 2012, 29 months.

Results were first posted in Sep 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2009
First posted
Dec 2, 2009
StartActual
Jun 1, 2010
Primary completionActual
Nov 2, 2012
CompletionActual
Nov 30, 2012
Results first posted
Sep 13, 2013
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01023841
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Dec 2, 2009
Start date
Jun 1, 2010
Primary completion
Nov 2, 2012
Completion
Nov 30, 2012
Results posted
Sep 13, 2013
Last update
Apr 17, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost Ophthalmic Solution

Start the discussion